-
Gemtuzumab ozogamicin, sold
under the
brand name Mylotarg, is an antibody-drug
conjugate (a drug-linked
monoclonal antibody) that is used to
treat acute...
-
Gemtuzumab Ozogamicin:
Reintroduction Based on
Favorable Risk:Benefit Profile". ADCReview.
September 2, 2017.
Retrieved August 14, 2024. "
Gemtuzumab Ozogamicin...
- proteins, its
expression is
known to be tied to TREM2. CD33 is the
target of
gemtuzumab ozogamicin (trade name: Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories),...
- FDA for
cancer include:
Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab...
-
release from the
differentiating promyelocytes. The
monoclonal antibody gemtuzumab ozogamicin has been used
successfully as a
treatment for APL, although...
- bullet" due to
their targeting properties. In 2001 Pfizer/Wyeth's drug
Gemtuzumab ozogamicin (trade name: Mylotarg) was
approved based on a
study with a...
-
traditional systemic approaches. The
first approved drug of this type was
gemtuzumab ozogamicin (Mylotarg),
released by
Wyeth (now Pfizer). The drug was approved...
- dimethylhydrazide. It
includes the same linker,
called "AcBut", and toxin, as
gemtuzumab ozogamicin,
which arose from the same collaboration. The
linker is a carbonyl-containing...
-
approved for AML in the U.S.,
including venetoclax (BCL2 inhibitor),
gemtuzumab ozogamicin (CD33 antibody-drug conjugate), and
several inhibitors targeting...
-
Toripalimab L01FG01
Bevacizumab L01FG02
Ramucirumab L01FX01
Edrecolomab L01FX02
Gemtuzumab ozogamicin L01FX03
Catumaxomab L01FX04
Ipilimumab L01FX05 Brentuximab...
